A multicenter, randomized, controlled trial of 610 patients with chronic hepatitis C infected with HCV genotype 1 or 4 compared 48 weeks of standard of care therapy (PEG-IFN and ribavirin) with 12 weeks of induction therapy with high-dose PEG-IFN followed by 36 weeks of standard of care treatment. High-dose PEG-IFN induction therapy did not enhance early or sustained virologic response rates compared with standard of care therapy.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Zeuzem, S. Induction therapy in chronic hepatitis C: déjà-vu with pegylated interferons. J. Hepatol. 41, 488–490 (2004).
Roberts, S. K. et al. Impact of high-dose peginterferon alfa-2A on virological response rates in patients with hepatitis C genotype 1: a randomized trial. Hepatology 50, 1045–1055 (2009).
Brady, D. E. et al. Induction pegylated interferon alfa-2b in combination with ribavirin in patients with genotypes 1 and 4 chronic hepatitis C: a prospective, randomized, multicenter, open-label study. Clin. Gastroenterol. Hepatol. 8, 66–71 (2010).
Neumann, A. U. et al. Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy. Science 282, 103–107 (1998).
Buti, M. et al. Viral kinetics in genotype 1 chronic hepatitis C patients during therapy with 2 different doses of peginterferon alfa-2b plus ribavirin. Hepatology 35, 930–936 (2002).
Horner, S. M. & Gale, M. Jr. Intracellular innate immune cascades and interferon defenses that control hepatitis C virus. J. Interferon Cytokine Res. 29, 489–498 (2009).
Ge, D. et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 461, 399–401 (2009).
Fischer, R., Baumert, T. & Blum, H. E. Hepatitis C virus infection and apoptosis. World J. Gastroenterol. 13, 4865–4872 (2007).
Lee, S. S. & Ferenci, P. Optimizing outcomes in patients with hepatitis C virus genotype 1 or 4. Antivir. Ther. 13 (Suppl. 1), 9–16 (2008).
Jensen, D. M. et al. Re-treatment of patients with chronic hepatitis C who do not respond to peginterferon-alpha2b: a randomized trial. Ann. Intern. Med. 150, 528–540 (2009).
Author information
Authors and Affiliations
Ethics declarations
Competing interests
P. Ferenci is a consultant for Roche, Novartis and Vertex. He is on the speakers bureau for Roche and Vertex, and receives grant/research support from Roche.
Rights and permissions
About this article
Cite this article
Ferenci, P. Treatment of chronic hepatitis C—how much interferon is enough?. Nat Rev Gastroenterol Hepatol 7, 191–193 (2010). https://doi.org/10.1038/nrgastro.2010.40
Issue Date:
DOI: https://doi.org/10.1038/nrgastro.2010.40
